Immunotherapy to address unmet needs in oncology; two clinical vignettes of response in metastatic malignant melanoma and non-small cell lung cancer

ABSTRACT

The management of unresectable advanced, metastatic malignant melanoma [MM] and chemotherapy-resistant or refractory non-small cell lung cancer [NSCLC] has been an uphill challenge in clinical oncology. The advent of immunotherapy in cancer has put forward some new hopes to cover unmet needs in treating such cases. Immune-checkpoint inhibitors are among the well-supported options in the same vein. Alongside other cancer immunotherapy class-molecules, pembrolizumab [PZB], a programmed cell death protein 1 [PD-1] blocking antibody, has recently been approved both for MM and NSCLC. This report presents an overview of the clinical benefits of PZB in MM and NSCLC and highlights the clinical features of two eligible cases who have undergone immunotherapy using PZB